News | June 17, 2025
Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Subscribe To Our Newsletter & Stay Updated
